Safety and efficacy of cilostazol in the management of intermittent claudication
Authors:
- Yung-Wei ChiYCYung-Wei Chi
- Carl J LavieCLCarl J Lavie
- Christopher J WhiteCWChristopher J White
Open Access
- 1 December 2008
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (6) , 1197-1203
Abstract
Safety and efficacy of cilostazol in the management of intermittent claudication Yung-Wei Chi, Carl J Lavie, Richard V Milani, Christopher J WhiteDepartment of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.Keywords: peripheral arterial disease, cilostazol, intermittent claudication, supervised exercise therapyKeywords
This publication has 37 references indexed in Scilit:
- Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet ActivationEuropean Journal of Vascular and Endovascular Surgery, 2009
- Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery DiseaseClinical Journal of the American Society of Nephrology, 2008
- Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patientsPharmacological Research, 2007
- The Cardioprotective Effect of a Statin and Cilostazol Combination: Relationship to Akt and Endothelial Nitric Oxide Synthase ActivationCardiovascular Drugs and Therapy, 2007
- Coronary Stent Restenosis in Patients Treated With CilostazolCirculation, 2005
- CilostazolAmerican Journal of Cardiovascular Drugs, 2003
- Pharmacologic therapy for peripheral arterial disease and claudicationJournal of Vascular Surgery, 2002
- Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study)The American Journal of Cardiology, 2001
- Exercise for intermittent claudication2000
- Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in CultureJournal of Cardiovascular Pharmacology, 1992